A trivalent recombinant Ad5 gag/pol/nef vaccine fails to protect rhesus macaques from infection or control virus replication after a limiting-dose heterologous SIV challenge

详细信息	查看全文 | 推荐本文 |

• 作者：Matthew R. Reynolds^a ; ^{mrreynol@wisc.edu} ; Andrea M. Weiler^a ; ^{amweiler@wisc.edu} ; Shari M. Piaskowski^a ; ^{sharip@primate.wisc.edu} ; Michael Piatak Jr.^b ; ^{Michael.Piatak2@nih.gov} ; Henry T. Robertson^c ; ^{HRobertson@ms.soph.uab.edu} ; David B. Allison^c ; ^{DAllison@ms.soph.uab.edu} ; Andrew J. Bett^d ; ^{andrew_bett@merck.com} ; Danilo R. Casimiro^d ; ^{danilo_casimiro@merck.com} ; John W. Shiver^d ; ^{john_shiver@merck.com} ; Nancy A. Wilson^a ; ^{nwilson@primate.wisc.edu} ; Jeffrey D. Lifson^b ; ^{Jeffrey.Lifson@nih.gov} ; Wayne C. Koff^e ; ^{WKoff@iavi.org} ; David I. Watkins^a ; ^f ; ¹ ; ^{DWatkins@med.miami.edu}
• 关键词：rAd5 ; recombinant Adenovirus serotype 5 ; Mamu ; Macaca mulatta ; PCR-SSP ; PCR amplification with sequence-specific primers ; QRT-PCR ; quantitative reverse transcription-PCR
• 刊名：Vaccine
• 出版年：2012
• 期刊代码：89_0264410x
• 类别：imm
• 出版时间：22 June, 2012
• 卷：30
• 期：30
• 页码：4465-4475
• 文件大小：875 K

摘要

It has been suggested that poor immunogenicity may explain the lack of vaccine efficacy in preventing or controlling HIV infection in the Step trial. To investigate this issue we vaccinated eight Indian rhesus macaques with a trivalent replication-incompetent adenovirus serotype 5 vaccine expressing SIV Gag, Pol, and Nef using a regimen similar to that employed in the Step trial. We detected broad vaccine-induced CD8⁺ (2-7 pool-specific responses) and CD4⁺ (5-19 pool-specific responses) T-cell responses in IFN-纬 ELISPOT assays at one week post-boost using fresh PBMC. However, using cryopreserved cells at one and four weeks post-boost we observed a reduction in both the number and magnitude of most vaccine-induced responses. This demonstrates that the time points and conditions chosen to perform immune assays may influence the observed breadth and frequency of vaccine-induced T-cell responses. To evaluate protective efficacy, we challenged the immunized macaques, along with na茂ve controls, with repeated, limiting doses of the heterologous swarm isolate SIVsmE660. Vaccination did not significantly affect acquisition or control of virus replication in vaccinees compared to na茂ve controls. Post-infection we observed an average of only two anamnestic CD8⁺ T-cell responses per animal, which may not have been sufficiently broad to control heterologous virus replication. While the trivalent vaccine regimen induced relatively broad T-cell responses in rhesus macaques, it failed to protect against infection or control viral replication. Our results are consistent with those observed in the Step trial and indicate that SIV immunization and challenge studies in macaque models of HIV infection can be informative in assessing pre-clinical HIV vaccines.